Our pipeline of SPEARs™ target transcription factors and regulatory pathways of disease that make cells cancerous or dampen the immune system against tumors
| Program/Target | Indication(s)/Settings | Discovery | IND-Enabling | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
| ST101 C/EBPβ | ST101-101 Phase 1/2 Study | |||||
| ST101 C/EBPβ | Phase 1: Dose Escalation | |||||
| ST101 C/EBPβ | All-Comers/Solid | Complete | ||||
| ST101 C/EBPβ | Phase 2: Dose Expansion | |||||
| ST101 C/EBPβ | Recurrent GBM †* | |||||
| ST101 C/EBPβ | Metastatic Cutaneous Melanoma †* | |||||
| ST101 C/EBPβ | Castration-Resistant Prostate | |||||
| ST101 C/EBPβ | HR+ Breast | |||||
| ST101 C/EBPβ | Neo-adjuvant Recurrent GBM †* | |||||
| ST101 C/EBPβ | Neo-adjuvant Primary GBM* (ComboTx) | |||||
| ST316 β-catenin (Wnt pathway) |
Solid | |||||
| JunAP cJun (AP1 complex) | Solid and heme | |||||
| FoxAP FOXP3 | Solid and heme (ComboTx) | |||||
| ST101 C/EBPβ |
| ST101-101 Phase 1/2 Study |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| ST101 C/EBPβ |
| Phase 1: Dose Escalation |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| ST101 C/EBPβ |
| All-Comers/Solid |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
Complete |
| ST101 C/EBPβ |
| Phase 2: Dose Expansion |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| ST101 C/EBPβ |
| Recurrent GBM †* |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| ST101 C/EBPβ |
| Metastatic Cutaneous Melanoma †* |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| ST101 C/EBPβ |
| Castration-Resistant Prostate |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| ST101 C/EBPβ |
| HR+ Breast |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| ST101 C/EBPβ |
| Neo-adjuvant Recurrent GBM †* |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| ST101 C/EBPβ |
| Neo-adjuvant Primary GBM* (ComboTx) |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| ST316 β-catenin (Wnt pathway) |
| Solid |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| JunAP cJun (AP1 complex) |
| Solid and heme |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| FoxAP FOXP3 |
| Solid and heme (ComboTx) |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
†FDA Fast Track Designantion *FDA Orphan Drug Designation